The 2020 National Xconomy Awards – celebrating the best in biotech innovation and entrepreneurship – just got bigger!
We’re excited to announce the expansion of the 2020 National Xconomy Awards. Presented in a digital format, the 2020... Read more »
One way that a cell regulates which genes in its DNA are expressed and when is by altering the structure of the fibers that are formed by the genetic material and associated proteins, packaging that’s referred to as chromatin.
Foghorn Therapeutics,... Read more »
The federal government’s Operation Warp Speed has made its biggest financing award yet, promising $1.6 billion to a Maryland biotech to help advance its investigational COVID-19 vaccine and ready millions of doses in preparation for its possible success.
Gaithersburg, MD-based Novavax,... Read more »
Targeted therapies for treating cancer are designed to attack one or more proteins known to be on the surface of cancerous cells—but they don’t discriminate when they come across healthy cells expressing those same proteins.
Vor Biopharma, an oncology company launched... Read more »
Here’s a look back at some of the life science industry’s executive appointments, departures, and retirements from recent weeks:
—Pacific Biosciences (NASDAQ: PACB) CEO Michael Hunkapiller and Chief Financial Officer Susan Barnes are retiring.
—Moderna (NASDAQ: MRNA) appointed... Read more »
The same week Annexon Biosciences announced it had raised $100 million in private financing to advance its research of antibody drugs to treat neurodegeneration, the company filed paperwork with regulators indicating its intention to tap the public markets, too.
The South... Read more »
Bristol Myers Squibb likes what it sees from the immune cell research of Dragonfly Therapeutics so far—enough to pay $55 million to add multiple sclerosis and neuroinflammation to their ongoing partnership.
The alliance came to New York-based Bristol (NYSE: BMY)... Read more »
MEI Pharma and its Swiss partner Helsinn are ending a Phase 3 study of an investigational cancer drug for patients with acute myeloid leukemia (AML) after an interim analysis indicated it was unlikely to meet the trial’s main goal of helping... Read more »
Fast enrollment of the right patient populations will be critical to quickly conducting Phase III trials of COVID-19 vaccines and this will likely mean taking concerted steps to reach out to populations that can be harder to recruit for clinical trials,... Read more »
The quantity of data about medicines, diseases, and biology is growing. So too, are the number of companies that employ artificial intelligence in drug discovery. Most of the low-hanging fruit in drug research has already been picked, and the industry is... Read more »
Annexon Biosciences, a biotech founded in late 2014 by former Elan Pharmaceuticals executives, has added $100 million to its coffers to move its two clinical-stage programs along and to continue advancing its preclinical pipeline.
The South San Francisco-based company is developing... Read more »
[Updated 7/2/2020, 9:27 a.m. See below.] A BioNTech messenger RNA vaccine candidate for COVID-19 has shown in a small study that it can elicit an immune response to the novel coronavirus.
The 45-patient US study tested three doses of... Read more »
[Updated, 4:54 p.m.] Amylyx Pharmaceuticals’ two-pronged approach to neurodegenerative diseases has shown promise in amyotrophic lateral sclerosis (ALS) testing and the company now has $30 million to complete a separate clinical trial in Alzheimer’s disease.
The Series B round... Read more »